Celgene Corp Com (CELG) Holder Oaktop Capital Management Ii LP Decreased Its Position by $8.02 Million as Share Price Rose

September 16, 2018 - By Victoria Pittman

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment decreased to 0.71 in 2018 Q2. Its down 0.08, from 0.79 in 2018Q1. It is negative, as 68 investors sold CELG shares while 495 reduced holdings. 98 funds opened positions while 300 raised stakes. 476.86 million shares or 7.08% less from 513.18 million shares in 2018Q1 were reported. Hrt Fincl Ltd Liability Corp reported 13,436 shares. Jpmorgan Chase & holds 0.07% or 4.34M shares in its portfolio. Busey reported 0.57% in Celgene Corporation (NASDAQ:CELG). Archford Capital Strategies Limited Liability Corporation holds 1,586 shares. Nordea Invest stated it has 208,010 shares or 0.04% of all its holdings. Bainco Int Invsts owns 0.83% invested in Celgene Corporation (NASDAQ:CELG) for 73,072 shares. Adirondack Tru Communications holds 0.23% or 4,154 shares in its portfolio. Legal & General Grp Pcl has invested 0.2% in Celgene Corporation (NASDAQ:CELG). Moreover, Parametric Port Associate Ltd Liability has 0.13% invested in Celgene Corporation (NASDAQ:CELG). Amica Pension Fund Board Of Trustees invested 0.34% of its portfolio in Celgene Corporation (NASDAQ:CELG). Proshare Advsrs Ltd owns 781,654 shares or 0.42% of their US portfolio. John G Ullman & Associate Incorporated holds 0.08% or 5,208 shares in its portfolio. Griffin Asset Mngmt invested in 0.15% or 10,215 shares. New Mexico Educational Retirement Board, New Mexico-based fund reported 69,330 shares. Cadence National Bank & Trust Na invested 0.17% in Celgene Corporation (NASDAQ:CELG).

Since May 8, 2018, it had 1 insider buy, and 2 sales for $2.33 million activity. Shares for $99,784 were bought by Alles Mark J on Tuesday, May 8. CASEY MICHAEL D sold 13,000 shares worth $1.02M.

Oaktop Capital Management Ii Lp decreased its stake in Celgene Corp Com (CELG) by 4.69% based on its latest 2018Q2 regulatory filing with the SEC. Oaktop Capital Management Ii Lp sold 101,559 shares as the company’s stock rose 12.17% with the market. The hedge fund held 2.06 million shares of the major pharmaceuticals company at the end of 2018Q2, valued at $163.99 million, down from 2.17 million at the end of the previous reported quarter. Oaktop Capital Management Ii Lp who had been investing in Celgene Corp Com for a number of months, seems to be less bullish one the $61.31 billion market cap company. The stock decreased 1.77% or $1.57 during the last trading session, reaching $87.17. About 3.54M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 38.90% since September 16, 2017 and is downtrending. It has underperformed by 54.52% the S&P500.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on October, 25. They expect $2.00 earnings per share, up 12.36 % or $0.22 from last year’s $1.78 per share. CELG’s profit will be $1.41B for 10.90 P/E if the $2.00 EPS becomes a reality. After $1.86 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 7.53 % EPS growth.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “Trade of the Day: Celgene Is Coiling Up for a Rally” on August 29, 2018, also Seekingalpha.com with their article: “Will Revlimid’s Patent Protection Hold Up For Celgene?” published on September 05, 2018, Fool.com published: “Why bluebird and Celgene Should Worry About Amgen’s Latest Clinical Victory” on September 14, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Nasdaq.com and their article: “3 Biotech Stocks Analysts Say Are Market Winners” published on September 13, 2018 as well as Fool.com‘s news article titled: “Better Buy: Celgene Corporation vs. Bristol-Myers Squibb” with publication date: August 20, 2018.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 10 analysts covering Celgene (NASDAQ:CELG), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Celgene has $16300 highest and $90 lowest target. $118.50’s average target is 35.94% above currents $87.17 stock price. Celgene had 15 analyst reports since March 21, 2018 according to SRatingsIntel. Morgan Stanley maintained Celgene Corporation (NASDAQ:CELG) on Monday, May 7 with “Equal-Weight” rating. The company was upgraded on Wednesday, May 23 by Bernstein. RBC Capital Markets downgraded Celgene Corporation (NASDAQ:CELG) on Monday, May 7 to “Outperform” rating. Standpoint Research upgraded the shares of CELG in report on Monday, June 18 to “Buy” rating. JP Morgan maintained it with “Overweight” rating and $110 target in Wednesday, March 21 report. Morgan Stanley maintained Celgene Corporation (NASDAQ:CELG) on Friday, July 27 with “Equal-Weight” rating. The firm earned “Equal-Weight” rating on Friday, July 13 by Morgan Stanley. Leerink Swann maintained Celgene Corporation (NASDAQ:CELG) rating on Monday, May 7. Leerink Swann has “Buy” rating and $11500 target. The stock has “Buy” rating by RBC Capital Markets on Wednesday, April 4. The stock of Celgene Corporation (NASDAQ:CELG) has “Hold” rating given on Thursday, May 31 by Cantor Fitzgerald.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.